Provided by Tiger Fintech (Singapore) Pte. Ltd.

Precision Biosciences Inc

5.33
-0.1700-3.09%
Post-market: 5.330.00000.00%17:06 EDT
Volume:69.47K
Turnover:373.55K
Market Cap:55.87M
PE:5.13
High:5.68
Open:5.49
Low:5.16
Close:5.50
Loading ...

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025

Business Wire
·
21 Mar

Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025

Business Wire
·
20 Mar

Precision Biosciences Price Target Maintained With a $60.00/Share by HC Wainwright & Co.

Dow Jones
·
20 Mar

Precision BioSciences presents preclinical data from PBGENE-DMD program

TIPRANKS
·
19 Mar

Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Business Wire
·
19 Mar

Precision Says its Investigational New Drug Application for Hepatitis B Treatment Gets US FDA's Clearance

MT Newswires Live
·
17 Mar

Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class Pbgene-Hbv Designed to Eliminate Root Cause of Chronic Hepatitis B

THOMSON REUTERS
·
17 Mar

Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B

Business Wire
·
17 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
14 Mar

Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

THOMSON REUTERS
·
24 Feb

Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Business Wire
·
24 Feb

Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate

Benzinga
·
20 Feb

Precision Biosciences Price Target Maintained With a $60.00/Share by HC Wainwright & Co.

Dow Jones
·
20 Feb

BRIEF-Precision Biosciences Announces Initial Safety And Antiviral Activity Of Pbgene-Hbv

Reuters
·
19 Feb

Precision BioSciences Announces Initial Safety and Antiviral Activity of Pbgene-Hbv in the Eliminate-B Clinical Trial

THOMSON REUTERS
·
19 Feb

Precision BioSciences Inc - Pbgene-Hbv Safe and Well Tolerated in Initial Study

THOMSON REUTERS
·
19 Feb

Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial

Business Wire
·
19 Feb

Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple in Vivo Gene Editing Programs

THOMSON REUTERS
·
29 Jan

Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs

Business Wire
·
29 Jan

Precision BioSciences Shares Up After Upgrade From BMO Capital, Positive Date From Gene Therapy Study

MT Newswires Live
·
11 Jan